NCT00425477: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
|
|
| Completed | 2 | 26 | US | sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases | 09/16 | 09/16 | | |
